CD274 and cancer: Single-agent and combinations of PD-1, PD-L1 or CTLA-4 inhibitors in patients with advanced PDAC are ineffective (objective response rates (ORRs) <5%)4–6, including in patients with positive PD-L1 expression, a biomarker that enriches for response in other cancers.